As another year whizzes past, we find ourselves wondering where 2024 went! While most of us are still trying to find our missing New Year’s resolutions from January, our Prime Funds have been hard at work in what can only be described as a rollercoaster of a year.

In this report, we will take a look at how our recommendations in Prime Funds fared for the calendar 2024.

Prime Funds performance in 2024

What we did in 2024

In Prime Funds, changes we make are usually from a long-term perspective. However, we try to add tactical funds to make the most of a particular opportunity whether its in thematic equity funds or in debt funds. these are more from a short-term perspective and are intended to add some diversification or return booster to your portfolio.

In 2024, we have not made many or big changes to any of our Prime Funds categories. Market conditions were getting trickier to navigate both in equity and in debt. Equity markets saw mixed signals between earnings growth, index levels, IPO offtake, yo-yoing mid and smallcap space, and global cues. Debt markets dealt with the RBI holding rates steady against rate cuts in the US, which lead to market rates trending lower even without a repo cut.

Our choices, therefore, were aimed at capturing these moves in debt markets, sector-specific movement in equity markets and in aggressive equity funds, to prioritise protecting risks along with returns rather than focusing on maximising returns alone.

One action in this direction was to introduce a new category within equity funds – the Equity High-Risk Turnarounds. This was to help add funds that were picking up in returns but hand not yet established a steady outperformance, in order to catch performers early. We have also, in line with what we had mentioned in 2023, further pruned underperformers where it was clear it was getting tougher for funds to recover. 

Let’s now move on to how our recommendations fared.

Equity funds

Our equity fund recommendations have demonstrated strong performance across all categories. Our selection strategy prioritizes consistent outperformers rather than temporary chart toppers. This approach focuses on sustainable, long-term results over short-term gains.

Therefore our decision to remove funds from our recommended list happens after much deliberation. Apart from performance metrics it is also based on careful analysis of several factors:

  • Severity and duration of underperformance
  • Recovery potential assessment
  • Portfolio composition alignment with market conditions

When comparing our recommended funds’ performance against category averages, it’s important to note that category averages often include funds with unsustainable short-term spikes in performance. These temporary outperformers can artificially inflate category averages but typically don’t maintain their performance over time. Our Prime Funds selection process filters out such volatile performers to focus on funds with more reliable, consistent returns.

Equity – Moderate

The Nifty 50 spent the first half of the year in a flattish phase, until the general elections sparked a quick, sharp rally. Global cues, an FPI sell-off, and earnings disappointments then sent markets into an abrupt decline from October onwards. However, the broader sector pick up over the past several quarters has gradually helped large-cap based funds cement their outperformance over the Nifty 100 index. 

We had earlier been wary of adding multiple pure large-cap funds into Prime Funds given that outperformance was thin; we preferred flexi-cap funds. given the stable performance and the broader sector and economic recovery, we saw more potential in the large-cap category and therefore looked to include more such funds in Prime Funds. 

In the Equity – Moderate Prime Funds set, we draw from the large-cap and flexi-cap categories, as well as a couple from value/contra and focused if the fund is steadily large-cap oriented. The performance of this Prime Funds category is as follows:

This Prime Funds set has outperformed both the benchmark Nifty 100 TRI as well as the average for the categories from which we take funds. 

  • Our method of picking large-cap based funds from categories outside just pure large-cap has helped identify strong performers such as ICICI Pru Focused Equity. Invesco India Contra has also done well – this fund’s performance is in fact a showcase of our approach to waiting out bouts of underperformance where the portfolio, strategy and long-term record are sound.
  • We removed Mirae Asset Largecap in our December 2023 quarter review (done in January 2024); this was a fund we had mentioned in our 2023 Prime Funds round-up as one where performance was steadily worsening and on which we wanted to take a call on pruning.
  • In the Passive section of Equity Moderate (returns are not included in the above table), our addition of the Nifty 50 Value 20 was a good one as it closed with a 23% YTD return against the Nifty 100’s 18.6%. The other passive funds in our recommendation list are Nifty 50 & Sensex index funds.

Equity – Aggressive

This Prime Funds category consists of all funds that lean towards mid and smallcap allocations. 

We had shown disappointing performance of this Prime Funds category in 2023, owing to severe underperformance of two funds. The returns of the Prime Funds, then, had also been comparatively lower as we had fewer smallcap representation in a year of a runaway smallcap rally.

We had, at the time, and in our quarterly reviews stressed on two points – one, the rally in the mid and smallcap space was overheated and chasing returns alone without considering risks was avoidable. Two, the nature of the rally meant that funds with strategies rooted in stock fundamentals and quality lagged funds that were less choosy or more momentum-driven.

For these reasons, we refrained from changing much in this Prime Funds set in 2024. We simply removed the stark underperformers. We didn’t add unnecessary risk for the sake of returns and we retained funds which weren’t chart toppers but were still stable in their performance and which had strong portfolios. However, in order to introduce riskier return opportunities but still alert you to keep such risks contained in your portfolio, we introduced the High Risk – Turnaround set of Prime Funds. 

The performance of this entire Prime Funds set is as follows:

  • In 2024, we removed two big underperformers PGIM Flexicap and SBI Smallcap as their relative performance showed no signs of improvement. We also took a firm stance on Quant AMC funds and remove Quant Active – and performance has since deteriorated after we pulled the fund from the list.
  • Our focus on downside containment came into play in the sell-off in the past couple of months; barring a couple, all funds fell to a smaller extent than the Nifty 500 index (or their respective benchmarks). So, even though these funds weren’t the chart-toppers during the uptick eventual performance was still superior.
  • Our balanced approach when it comes to underperformance of funds helped; Kotak Emerging Equity, which was lagging both peers and benchmark in 2023, recovered well by 2024. Similarly, HDFC Smallcap and Nippon Smallcap are other stable performers but which are no longer at the top of the charts.
  • Our approach of using funds from different categories (other than midcap and smallcap) to add higher returns was a good move with picks such as Franklin India Opportunities and Kotak Multicap clocking handsome returns.

Equity – thematic

In this Prime Funds set, our calls on healthcare, IT and auto (logistics) played out well. Our two IT recommendations delivered a good 33-35% return, soundly trouncing the Nifty 500 TRI’s 21%. We had maintained our call on IT even during the phase where it was an underperformer, so that the full upside could be captured well.

For the same reason – of going against the tide in themes where conditions are lining up for better performance – we have continued to keep our banking recommendations even though they have undershot markets. 

We pulled out two cyclical themes in 2024 – auto and commodities – and advised you to book profits on them (when we removed them from Prime Funds) if you held them. Overall, the thematic Prime Funds recommendations returned 28.9% for 2024, a good outperformance over the Nifty 500 TRI.

Hybrid funds

Hybrid funds have come to the forefront after the change in debt taxation in 2023. Post that, we had been including more recommendations in Prime Funds. In hybrid funds, we look at the equity allocations, returns, volatility and downside containment to split it between the more conservative options (Hybrid Equity – Low Risk, suitable for short-term holdings and to partially replace debt in your portfolio) and the higher-returning funds (Hybrid Equity – Moderate Risk, suitable for longer-term holdings and a route to get more equity in a portfolio without as much risk). 

In 2024, we have not made much change in these recommendations; by and large, our fund choices have remained above average. The table below shows the performance of the Hybrid Equity – Moderate Risk performance in 2024. 

We removed Quant Absolute from this list, owing to the developments in the AMC. We also removed Canara Robeco Equity Hybrid as its performance compared to the other hybrid aggressive funds was dropping. Given the opportunity loss with continued investments, we replaced it with Kotak Equity Hybrid, which has been steadily improving performance. 

In the Hybrid Equity – Low Risk Prime Funds set, we have made no change at all in 2024; in fact, the last change we made here was to add UTI Equity Savings in June 2023. All our recommendations have steadily delivered above average.

Debt funds

Debt funds have had a much quieter year in 2024 over the year before – a changing rate cycle and tax structure both served to make 2023 a very eventful year for debt funds. However, 2024 saw a divergence between the actual action on repo rates and market interest rates; while repo rates have seen no cuts, bond yields already were moderating as we observed in our mid-year debt market review. Broadly, debt markets shaped up as we had explained in our 2024 debt market outlook, with continued concerns over inflation but with markets pre-empting RBI's rate cuts.

Therefore, our changes in debt funds for 2024 hinged on making the most of the remaining window of opportunity in bond price appreciation driven by yield moderation. We did this by adding funds that used a part of their portfolio to play such duration opportunities, across our Prime Funds categories. We also recommended following a barbell strategy of holding funds of different maturities to bring in accrual opportunities as yields were attractive while simultaneously gaining from bond price appreciation.

Debt – Very Short Term

Apart from removing Nippon Low Duration and adding Kotak Money Market in this Prime Funds set, we have made no changes. Even this fund change was primarily due to the very short-term holding period of these funds, where the Kotak fund offered marginally higher portfolio yields. Our performance in this Prime Funds set continues to remain healthy.

Debt – Short Term

This is one category where we tried to introduce tactical opportunities to capitalise on bond price appreciation. We added ICICI Pru Banking & PSU Debt Fund, initially, which used its gilt exposure effectively to play the yield decline. Owing to it increasing its maturity profile, we later moved it to the Debt – Medium Term category. In its place, we moved ICICI Pru Short Term from Debt – Medium Term into the Short Term category as its maturity profile was more suitable and which still had a similar strategy of duration calls.

  • The Debt Short Term Prime Funds set also includes funds from the floating rate funds category. This debt category is a mix of funds with varying maturity profiles and accrual/duration strategies and therefore we have avoid the very aggressive ones. Our two floater funds in this Prime Funds set – HDFC Floating Rate and Nippon India Floating Rate have both delivered on par with the category average in 2024; the average is influenced by high returns from some funds. if we remove these outliers, the category average in the table above drops to 8%.
  • Outside the floating rate funds, the other Prime Funds from the short duration and banking & PSU categories are all above average.

Debt – Medium Term & Debt – Long Term

In these Prime Funds sets, we pull from different categories where the average portfolio maturity is longer than 2-3 years or the strategy requires a longer holding period. 

The Debt – Long Term Prime Funds set is the second set where we added funds to capitalise on duration and the opportunity in gilts. In addition to SBI Constant Maturity that we already had in the set, we added two more pure gilt funds. We had retained the constant maturity fund through the low-return period of 2022 and much of 2023; gilts and these funds have come back sharply as gilt yields dropped, clocking returns in excess of 9% in 2024.

The other move we made in these Prime Funds sets is to go slow on credit risk funds. We observed that both yields and returns in credit risk funds were not significantly different from corporate bond or medium duration funds. Therefore, we removed HDFC Credit Risk and retained only ICICI Pru Credit Risk as the credit risk representation.

Overall, our performance in this Prime Funds set is as follows:

  • The marginal underperformance over the category average is primarily due to the high gilt return that skews the average; the average return of the both corporate bond fund and credit risk fund categories, for example, is 8.2%.
  • Our performance average is also slightly influenced by the lower return of ICICI Pru Corporate Bond fund, compared to the other corporate bond funds. If we remove this fund, the average moves up to 8.8%. ICICI Pru Corporate Bond is a consistent above-average performer with higher portfolio yields and we’re not worried by this shorter-term relative performance dip.
  • Given our outlook on rate direction, we had additionally given tactical calls in 2023 (as well as earlier in 2022) to gain from the downward rate movement. These calls are paying off; our latest such call was on constant maturity funds in October 2023, with returns on SBI Constant Maturity and ICICI Pru Constant Maturity delivering 11.6% and 10.4% (absolute) respectively.

Overall, all our Prime Funds recommendations have by and large beaten their respective benchmarks/categories. While some may perceive our portfolio adjustments as frequent, we've only made changes when compelling evidence suggested that continuing with some of them may significantly impact returns and also result in opportunity loss.

Looking ahead, we'll maintain our disciplined approach to fund selection, adapting our strategy as market dynamics and fund performance patterns evolve. Our quarterly review process remains a cornerstone of our methodology, enabling timely identification of both opportunities and challenges.

Here's to a prosperous 2025 filled with continued success in your investment journey!

More like this

16 thoughts on “Prime Funds performance in 2024”

  1. Hello PI team – Great article and interesting insights as we wrap up 2024.

    I always had this question. I have few funds which are in your sell list. But due to LTCG exemption limit of 1.25L , this is holding me from moving it from Underperforming Fund A to PI Recommended Fund B given that the profit is quite substantial.

    what should be the ideal course of action in your view? Bite the bullet , sell off , pay LTCG and invest in right fund or wait for April next year.

    1. Hello Sir, Happy new year! You have to make the decision 🙂 We provide recommendation on the product. The implications of the same on your portfolio is something you would need to follow. If you ask my personal experience, I do not think twice about exiting a fund or booking profit. To me tax is on the gain (unless one is booking a loss) and therefore I am not technically paying anything extra from my pocket. A part of my gain is gone towards tax. If you need to do this as a calculation, try using the excel given in this article to see if you lose much my switching. https://primeinvestor.in/reports/switching-between-funds/

  2. I have been an active follower of your recos but the fact of the matter is , my returns are nowhere close to yours because of same reason, another subscriber (Saravanan) has quoted above. I am in a constant rebalancing mode , with a bloated portfolio of funds. PGIM is off my stable at last but SBI small and Quant funds will take their time, due to draconian LTCG and exit loads. Same is the case with Mirae ELSS. By the time, I align my PF closer to the Prime funds list, something else changes and the shiny returns % stays in paper but not in the PF of investors like me.

  3. Thanks for the insight.
    Do you include the performances of the funds that were replaced from the Prime Recommended Funds?
    I happen to hold some funds(in large quantities) which were once in the recommended list but is no longer. And those funds are performing poorly in a 3 year timeframe(I totally understand for active funds 3 years is less), but does that impact your total calculation?

    1. No, we don’t include performance of funds removed from Prime Funds. Please refer to the Buy/Sell/Hold calls to know what to do – in most cases, the call will be a hold, since we will be watching performance. Also note that the performance we have explained above is for 2024 alone – it’s an annual exercise we undertake to explain how we did. – thanks, Bhavna

  4. Under thematic category, can you also evaluate and include a momentum/quant fund option? There are multiple fund houses now offer this strategy. Quant as a factor has proven to be performing well in Indian markets across cycles. Request you to consider this for the investors.

    1. We have written about momentum and have clearly stated we would not be comfortable adding it to Prime Funds. You may choose to use it for your tactical holding. On Quant, if you mean factor indices, we do consider them on and off. If you mean Quant strategy by active funds, we have yet to come across one that has performed across cycles. if you have any specific fund, you can write to us through contact and we will check. Thanks Vidya

  5. Rajasekar Shanmugavel

    Hello,

    Can we have the turnover ratio of funds under each category. WRT the change of funds in each category in past one year/2 Year.

    Eg. funds at start of year are A,B,C,D
    Funds at end of year are C,D,E,F
    Turnover ratio: 50%

    This can just through some light on frequency of change for eveyones better understanding.

    Under moderate n aggressive category of prime funds pls.

    Thanks
    Rajasekar

  6. Thanks for the report. Pruning and adding in model portfolio is always easier than in actual ones. For example, when I did yearly review of my portfolio in Dec 2023, I found Axis midcap fund in the buy list and invesco contra fund not in buy list. However things have changed in this one year. I continued SIP in both the funds and now Axis is in sell list. I find it always difficult to sell because of tax concerns and the dilemma in re-deployment as well. Meanwhile, there are turnarounds like ICICI pru value discovery as well as the invesco contra fund. Pause the SIP and Hold has increased the count of MF as well. MF review pro also says, you have too many funds. I am not clear on how to proceed when sell calls and buy calls come as I am mostly an SIP investor and not bulk investor. Please guide.

    Thanks, Saravanan

    1. Invesco Contra has always been in the buy list….it’s been a part of Prime Funds from the time we started out 🙂 Axis Midcap has been a Sell from June 2023 and was a Hold for several quarters before that. As far as call changes go – as explained in our post, we don’t pull out funds from the list at the first sign of underperformance. Similarly, in the buy/sell/hold calls, we don’t change the calls frequently. To this extent, the churn in a portfolio is unlikely to be high.

      So, as long as a fund is a buy or a hold, retain it in your portfolio and continue with your SIPs as usual. Only a sell call needs to be acted on, since there is an opportunity cost involved. You can make such exits in phases, to minimise tax impact. In active funds, such shifting is par for the course, provided it is not happening every other month. It’s enough if you review about once or twice a year. If your aim is to keep such tracking and shifting to a minimum, you can include more passive options in your portfolio. – thanks, Bhavana

  7. Trying to identify the next performing active fund is a pointless pursuit. Alternatives? Follow the
    advice of Bogle and go passive. But in India, we have a regulator who does not necessarily work
    in the favour of retail investors. There is a good chance, in time, dubious companies with govt
    blessings may dominate the major index. What does the hapless investor do? Thoughts?

    1. We’re not trying to identify the ‘next’ performing active fund 🙂 There are plenty of active funds that beat their benchmarks steadily, which is what we give in Prime Funds. It’s only when you chase the top performers that it becomes a difficult game. But yes, maintaining part of your portfolio in index funds is always a good move; as we have said before, using a blend of passive (especially in largecaps) and active helps earn market returns, mitigates risk, and still provides the ability to earn more. – thanks, Bhavana

Leave a Comment

Hold On

You are being redirected to another page,
it may take a few seconds.
Login to your account
OR

Become a PrimeInvestor!

Get stock & mutual fund recommendations

Start registration

Start registration

OR
user icon
user icon
user icon

Terms & Conditions

A copy of the T&C has been sent to your email.

Last modified on February 18, 2025

This website www.primeinvestor.in (“Website”) is owned and operated by PrimeInvestor Financial Research Pvt. Ltd. (“RA”), a SEBI-registered Research Analyst with Registration No. INH200008653.

Through the Website, the RA allows clients to access research recommendations, research reports, and model portfolios, along with tools, personal finance products, and articles, on the payment of a subscription fee (“Research Services”). The terms ‘RA’ or ‘us’ or ‘we’ refer to PrimeInvestor Financial Research Pvt Ltd (SEBI RA Registration No INH200008653) who are the owners of this Website and offering the Research Services. The term ‘you’ and ‘client’ refers to the subscriber of the Services on the Website. The RA provides the Research Services subject to the notices, terms, and conditions set forth in these Terms. By accepting these Terms when you subscribe to the Research Services, you provide your consent to abide by these Terms.

Most Important Terms and Conditions (MITC)

[Forming part of the Terms and Conditions for providing research services]

  1. These terms and conditions, and consent thereon are for the research services provided by the Research Analyst (RA) and RA cannot execute/carry out any trade (purchase/sell transaction) on behalf of the client. Thus, the clients are advised not to permit RA to execute any trade on their behalf.
  2. The fee charged by RA to the client will be subject to the maximum amount prescribed by SEBI/ Research Analyst Administration and Supervisory Body (RAASB) from time to time (applicable only for Individual and HUF Clients).
    Note:
    • SEBI's current cap on fee is Rs 1,51,000/- per annum per family of client for all research services of the RA.
    • The fee limit does not include statutory charges.
    • The fee limits do not apply to a non-individual client / accredited investor.
  3. RA may charge fees in advance if agreed by the client. Such advance shall not exceed the period stipulated by SEBI; presently it is one quarter. In case of pre-mature termination of the RA services by either the client or the RA, the client shall be entitled to seek refund of proportionate fees only for the unexpired period.
  4. Fees to RA may be paid by the client through any of the specified modes like cheque, online bank transfer, UPI, etc. Cash payment is not allowed. Optionally the client can make payments through Centralized Fee Collection Mechanism (CeFCoM) managed by BSE Limited (i.e. currently recognized RAASB).
  5. The RA is required to abide by the applicable regulations/ circulars/ directions specified by SEBI and RAASB from time to time in relation to disclosure and mitigation of any actual or potential conflict of interest. The RA will endeavor to promptly inform the client of any conflict of interest that may affect the services being rendered to the client.
  6. Any assured/guaranteed/fixed returns schemes or any other schemes of similar nature are prohibited by law. No scheme of this nature shall be offered to the client by the RA.
  7. The RA cannot guarantee returns, profits, accuracy, or risk-free investments from the use of the RA's research services. All opinions, projections, estimates of the RA are based on the analysis of available data under certain assumptions as of the date of preparation/publication of research report.
  8. Any investment made based on recommendations in research reports are subject to market risks, and recommendations do not provide any assurance of returns. There is no recourse to claim any losses incurred on the investments made based on the recommendations in the research report. Any reliance placed on the research report provided by the RA shall be as per the client's own judgement and assessment of the conclusions contained in the research report.
  9. The SEBI registration, Enlistment with RAASB, and NISM certification do not guarantee the performance of the RA or assure any returns to the client.
  10. For any grievances,
    • Step 1: the client should first contact the RA using the details on its website or following contact details:
      Customer care: [email protected]
      Grievance officer: [email protected], ATTN: Srikanth Meenakshi
      Compliance officer: [email protected], ATTN.: Bhavana Acharya
      Principal officer: [email protected], ATTN.: Vidya Bala
    • Step 2: If the resolution is unsatisfactory, the client can also lodge grievances through SEBI's SCORES platform at www.scores.sebi.gov.in
    • Step 3: The client may also consider the Online Dispute Resolution (ODR) through the Smart ODR portal at https://smartodr.in
  11. Clients are required to keep contact details, including email id and mobile number/s updated with the RA at all times.
  12. The RA shall never ask for the client’s login credentials and OTPs for the client’s Trading Account, Demat Account, and Bank Account. Never share such information with anyone including RA.

By browsing, viewing, using the Website and subscribing to the Research Services provided therein you consent to and agree to comply with these Terms and Conditions of subscription (“Terms”).

The RA reserves the right to change or modify the Website, the contents thereof and these Terms at any time. All modifications to these Terms & Conditions will be posted on the Website and will become effective immediately upon such posting. Changes once made will be communicated to the client. Continued use of the Website shall be construed as acceptance of the revisions to the Terms by conduct.

The following terms and conditions include but are not limited to minimum mandatory terms and conditions to clients as stipulated by SEBI.

1. Availing the research services

By accepting delivery of the research service, the client confirms that he/she has elected to subscribe to the research service of the RA at his/her sole discretion. The RA confirms that Research Services shall be rendered in accordance with the applicable provisions of the SEBI RA Regulations.

2. Obligations on RA

The RA shall be bound by the SEBI Act and all the applicable rules and regulations of SEBI, including the RA Regulations and relevant notifications of Government, as may be in force, from time to time.

3. Client Information and KYC

The client shall furnish all such details in full as may be required by the RA in its standard form with supporting details, if required, as may be made mandatory by Research Analyst Administration and Supervisory Body(RAASB)/SEBI from time to time. RA shall collect, store, upload and check KYC records of the clients with KYC Registration Agency (KRA) as specified by SEBI from time to time.

4. Standard Terms of Service

The consent of client shall be taken on the following understanding:

“I / We have read and understood the terms and conditions applicable to a research analyst as defined under regulation 2(1)(u) of the SEBI (Research Analyst) Regulations, 2014, including the fee structure.

I/We are subscribing to the research services for our own benefits and consumption, and any reliance placed on the research report provided by research analyst shall be as per our own judgement and assessment of the conclusions contained in the research report.

I/We understand that –

  1. Any investment made based on the recommendations in the research report are subject to market risk.
  2. Recommendations in the research report do not provide any assurance of returns.
  3. There is no recourse to claim any losses incurred on the investments made based on the recommendations in the research report.”

The declaration of the RA is as follows:

  1. We are duly registered with SEBI as an RA pursuant to the SEBI (Research Analysts) Regulations, 2014 and our registration details are: registration no SEBI INH200008653, with registration date 19th August, 2021
  2. We have the registration and qualifications required to render the services contemplated under the RA Regulations, and the same are valid and subsisting;
  3. Research analyst services provided by us do not conflict with or violate any provision of law, rule or regulation, contract, or other instrument to which it is a party or to which any of its property is or may be subject;
  4. The maximum fee that may be charged by the RA is ₹1.51 lakhs per annum per family of client. Our current fee structure, the term and duration of our subscription for our Research Services, can be viewed on our website here: https://primeinvestor.in/prime-pricing
  5. The recommendations provided by us as part of the Research Services do not provide any assurance of returns.

5. Consideration and mode of payment

The client shall duly pay to the RA the agreed fees for the services that RA renders to the client and statutory charges, as applicable. Such fees and statutory charges shall be payable through the specified manner and mode(s)/ mechanism(s).

The payment of fees shall be through a mode that shows traceability of funds. Such modes include but are not limited to credit cards/debit cards/ UPI/ net banking or any other mode specified by SEBI from time to time. However, the fees shall not be in cash.

6. Risk factors

  1. Investments are subject to market risk. Investing or trading in financial products involves risk. Past performance of the recommendation is not an indication of future returns. Past performance of the RA is not an indicator of future performance. Past performance of the security is not an indication of future returns.
  2. There are no assurances or guarantees that the objectives of any investment in financial products will be achieved.
  3. The names of financial products mentioned herein do not in any manner indicate their prospects or returns. The performance in the equity may be adversely affected by the performance of individual companies, changes in the market place and industry specific and macro-economic factors.
  4. The performance of the investments/ products recommended by the RA are subject to a wide range of risks, including but not limited to: performance of the respective companies, changes in equity and debt market conditions, micro and macro factors and forces affecting equity and debt markets, general levels of interest rates and interest rate risk, credit risk, liquidity risk, reinvestment risk, economic slowdown, volatility & illiquidity of the stocks, risks associated with trading volumes, liquidity and settlement systems in equity and debt markets and/or such other circumstance beyond the control of the RA or any of its Associates.
  5. Other risk factors include that may affect the performance of the investments/ products recommended by the RA include but are not limited to economic policies, changes of Government and its policies, acts of God, acts of war, civil disturbance, sovereign action and /or such other acts/ circumstance beyond the control of the RA or any of its Associates.
  6. The recommendations provided by the RA as part of its Research Services may not be suitable to all categories of investors.
  7. The client should read all scheme and security related documents carefully before investing.
  8. Returns and performance figures mentioned in the research report represent past performance and should not be constituted to be future returns or guaranteed returns.

7. Conflict of interest

The RA shall adhere to the applicable regulations/ circulars/directions specified by SEBI from time to time in relation to disclosure and mitigation of any actual or potential conflict of interest. Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors. Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

General disclosures: PrimeInvestor Financial Research Pvt Ltd (with brand name PrimeInvestor) is an independent research entity offering research services on personal finance products to customers. We are a SEBI registered Research Analyst (Registration: INH200008653). PrimeInvestor Financial Research Pvt. Ltd., its employees, directors or agents, do not have any material adverse disciplinary history as on the date of publication of this report.

Restrictions on trading: To ensure no conflict of interest, the RA declares as follows:

  1. Personal trading activities of the individuals employed as research analysts shall be monitored, recorded and subject to a formal approval by the directors or compliance officer of PrimeInvestor Financial Research Private Limited.
  2. Research analysts employed by PrimeInvestor Financial Research Private Limited or their associates or relatives shall not:
    • Deal/ trade in stocks recommended/ tracked by the research analyst within 30 days before and five days after the publication of a research report;
    • Deal/ trade in securities that the research analyst reviews in a manner contrary to the given recommendation;
    • Purchase or receive securities of the issuer before the issuer's initial public offering, if the issuer is principally engaged in the same types of business as companies that the research analyst follows or recommends.

Disclosures with respect to Research and Recommendations Services:

  1. The RA or its directors or any of its officer/employee does not trade in securities which are subject matter of recommendation.
  2. The RA, or any of its officers, directors, employees, or subsidiaries have not received any compensation/ benefits whether monetary or in kind, from the AMC, company, government, bank or any other product manufacturer or third party, whose products are the subject of its Research Services or investment information.
  3. The Research Analysts who have prepared the research reports that form part of the Research Services (“Research Analyst”) certify that all of the views expressed in the research report accurately reflect their views about the subject company or subject security.
  4. The RA or directors or employees or Research Analyst certify that no part of their compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report.
  5. The Research Analyst has not served as director, officer or employee in the subject company, AMC or insurance company of the mutual fund or insurance policy that is the subject of this report, or company whose bonds, NCDs, fixed deposits or other savings products that is the subject of this report.
  6. The Research Analyst or their relatives do not have any known direct or indirect material conflict of interest including long/short positions in the subject company.
  7. The Research Analyst may hold investments in the stocks, mutual fund schemes, bonds, fixed deposits, insurance policies, or other products that are the subject of the recommendations provided as part of the Research Services. The Research Analyst certifies that they will not act in a manner contrary to their views on these securities except in the event of significant news or event or change in personal financial circumstances and without formal approval from the directors of PrimeInvestor Financial Research Pvt. Ltd. or the compliance officer.
  8. There are no actual or potential conflicts of interest arising from any connection to or association with any issuer of products/ securities, including any material information or facts that might compromise its objectivity or independence in the carrying on of the Research Services. Such conflict of interest shall be disclosed to the client as and when they arise.
  9. The RA or its directors or its employee or its associates have not managed or co-managed the public offering of any company. The RA or its directors or its employee or its associates have not received any compensation for investment banking or merchant banking of brokerage services from the subject company. The RA or its directors or its employee or its associates have not received any compensation for products or services other than above from the subject company. The RA or its directors or its employee or its associates have not received any compensation or other benefits from the Subject Company or 3rd party in connection with the research report/ recommendation.
  10. The subject company of its research recommendations was not a client of the RA or its directors or its employee or its associates during twelve months preceding the date of recommendation services provided.
  11. The RA or its directors or its employee or its associates has not served as an officer, director or employee of the subject company. Research Analysts has not been engaged in market making activity of the subject company.

PrimeInvestor Financial Research Pvt. Ltd., its Associates, the Research Analysts or their relatives holds ownership of 1% or more, in respect of the said issuer company(ies)? – NO

8. Termination of service and refund of fees:

The RA may terminate or suspend rendering of Research Services to the client in the following circumstances:

  1. On account of suspension/cancellation of registration of RA by SEBI. In case of suspension of certificate of registration of the RA for more than 60 (sixty) days or cancellation of the RA registration, RA shall refund the fees, on a pro rata basis for the period from the effective date of cancellation/ suspension to end of the client’s subscription period.
  2. The RA voluntarily chooses to terminate its Research Service. In the event of such termination of the Research Service, the RA shall refund the fees, on a pro rata basis for the period from the date of such termination of research service to end of the client’s subscription period.

9. Grievance redressal and dispute resolution:

Any grievance related to:

  1. nonreceipt of research report, or
  2. missing pages or inability to download the entire report, or
  3. any other deficiency in the research services provided by RA

shall be escalated promptly by the client to the person/employee designated by RA, in this behalf as under:

Name: Bhavana Acharya
Designation: Director & Compliance Officer, PrimeInvestor Financial Research Pvt Ltd
Email: [email protected]

The RA shall be responsible to resolve grievances within 7 (seven) business working days or such timelines as may be specified by SEBI under the RA Regulations.

RA shall redress grievances of the client in a timely and transparent manner. Any dispute between the RA and his client may be resolved through arbitration or through any other modes or mechanism as specified by SEBI from time to time.

If the client is not satisfied with the response of the RA, he/she can lodge his/her grievances with SEBI at scores.sebi.gov.in. Alternatively, the client may also write to any of the offices of SEBI. For any queries, feedback or assistance, please contact SEBI Office on Toll Free Helpline at 1800 22 7575 / 1800 266 7575

Details on grievances are available on the Website as follows: https://primeinvestor.in/ra-grievance/

10. Additional clauses:

Scope of the Research Service: The Research Services will be limited to providing independent research recommendation and shall not be involved in any advisory or portfolio allocation services. The Research Services are not meant to be tailor-made or customized solutions that specifically apply to each client based on his/her risk profile.

The RA never guarantees the returns on the recommendation provided. Investor shall take note that investment/trading in stocks/Index or other securities is always subject to market risk. Past performance is never a guarantee of same future results. The RA shall not be responsible for any loss to the Investors.

This service is not directed for access or use by anyone in a country, especially the USA, Canada or the European Union countries, where such use or access is unlawful or which may subject PrimeInvestor Financial Research Pvt Ltd or its affiliates to any registration or licensing requirement.

The Research Service, including recommendations, research reports, updates, and other information will be accessible through the RA’s website https://primeinvestor.in only. Such recommendations and updates will not be provided over phone calls.

Fees: Our current fee structure, the term and duration of our subscription for our Research Service, can be viewed on our website: https://primeinvestor.in/prime-pricing. Eligibility for any discounts is ascertained at the time the client subscribes. Any such discount and its tenure shall be at the discretion of the RA.

Subscription and access to content services fall under the purview of Goods and Services Tax (GST) as per the current indirect taxation policy, Government of India. Unless otherwise indicated, prices stated on our website are exclusive of applicable GST, any applicable value added tax (VAT) or other sales taxes. We are a business-to-consumer (B2C) service provider and we do not commit to provide any input tax credit on GST charged on subscription to our Research Service.

We may change the Subscription Fees and charges then in effect, or add new fees or charges which will take effect at the end of the client’s subscription period, by giving notice in advance and an opportunity to cancel renewal of the subscription.

Subscription Access & Renewal: Subscription to the Website commences immediately on the realisation of payment of the Subscription Fees. Subscriptions are set to be renewed automatically at the end of the subscription period.

Unless the client notifies us before the end of his/her subscription period, or the client cancels the auto-renewal mandate within the period specified by law, that the client does not wish to renew his/her subscription, the client’s subscription will renew for the period defined by the client’s subscription plan. We will charge the subscription using the same payment method that you previously used.

Although the client may notify to us his/her intention to his/her subscription, such notice will only take effect at the end of his/her then current subscription period, and he/she will not receive a refund other than as set out under Clause 8 in these Terms.

The client may notify us of his/her wish to cancel his/her subscription by sending an email to [email protected]. The client must provide at least 5 business days advance notice for this to be implemented.

Refunds: There can be no cancellation and refund of subscription fee paid once the subscription is active, other than as stated in Clause 8 of these Terms. If the client is entitled to a refund as specified under Clause 8 of these Terms, the RA will credit that refund to the card or other payment method used by the client to submit payment, unless it has expired - in which case the RA will contact the client to proceed with the refund. If we do issue a refund or credit due to circumstances outside the obligations specified under Clause 8, we are under no obligation to issue the same or a similar refund in the future.

General disclaimers: The recommendations made herein in the Research Services are expression of views and/or opinions and should not be deemed or construed to be advice for the purpose of purchase or sale of any security, nor a solicitation or offering on any investment/ trading opportunity on behalf of the company, AMC, insurance company, or issuer of security referred to herein.

The content and research reports generated by the RA does not constitute or is not intended to constitute an offer to buy or sell, or a solicitation to an offer to buy or sell financial products, units or securities.

The information/ opinion/ views mentioned in research reports or by the RA are not meant to serve as a professional guide to the client or recipients of this Report. The research report, recommendation, or any other content published by the RA do not assure or guarantee any minimum or fixed returns to the client or recipients of the reports/ recommendations/ content.

Use of this information is at the client’s own risk. The client must make his/ her own investment decisions based on his/her specific investment objective and financial position and using such independent advisors as he/she believes necessary. The services rendered by the RA are on a best-effort basis. All information in the content or research report of the RA is provided on an as is basis. Information is believed to be reliable but the RA does not warrant its completeness or accuracy and expressly disclaim all warranties and conditions of any kind, whether express or implied.

While due care has been taken to ensure that the disclosures, information, and opinions given are fair and reasonable, PrimeInvestor Financial Research Pvt Ltd and/or none of its officers, directors, partners, employees, agents, subsidiaries, affiliates or business associates shall be liable for any direct, indirect, special, incidental, consequential, punitive or exemplary damages, including lost profits arising in any way whatsoever from the information/ opinions/ views contained in the research report and recommendations that form part of the Research Service, and/or mails, social media or notifications issued by PrimeInvestor Financial Research Pvt Ltd or any other agency appointed/authorised by PrimeInvestor Financial Research Pvt Ltd. Returns and performance figures mentioned in the research report represent past performance and should not be constituted to be future returns or guaranteed returns.

Any agreements, transactions or other arrangements made between the client and any third party named on (or linked to from) the Website are at your own responsibility and entered into at your own risk. Any information that you receive via the Website, whether or not it is classified as “real time”, may have stopped being current by the time it reaches you. Market price information may be rounded up/down and therefore may not be entirely accurate.

The purpose of these disclosures is to provide essential information about the Research Services in a manner to assist and enable the prospective client/client in making an informed decision for engaging in Research Services before onboarding.

History, present business and background: PrimeInvestor Financial Research Private Limited is registered with SEBI as Research Analyst with registration no. INH200008653. The Research Analyst got its registration on August 19, 2021 and is engaged in offering research and recommendation services.

Disciplinary history: There are no pending material litigations or legal proceedings against the Research Analyst. As on date, no penalties / directions have been issued by SEBI under the SEBI Act or Regulations made thereunder against the Research Analyst relating to Research Analyst services.

Details of the RA's associates: No associates.

Usage of Website Content: This Website is controlled and operated by the RA. All material, including research reports, recommendations, portfolios, ratings, lists of financial products, illustrations, statements, opinions, views, photographs, products, images, artwork, designs, text, graphics, logos, button icons, images, audio and video clips and software (collectively, “Content”) are protected by copyrights, trademarks and other intellectual property rights that are owned and controlled by the RA or by other parties that have licensed their material to us.

Except where otherwise agreed in writing with the RA, material on the Website is solely for the client’s personal, non-commercial use. Except as provided below, the client must not copy, reproduce, republish, upload, post, transmit or distribute such material in any way, including by e-mail or other electronic means and whether directly or indirectly and the client must not assist any other person to do so.

Without the prior written consent of the RA, modification of the materials, use of the materials on any other web site or networked computer environment or use of the materials for any purpose other than personal, non-commercial use is a violation of the copyrights, trademarks and other proprietary rights, and is prohibited. Any use for which the client receives any remuneration, whether in money or otherwise, is a commercial use for the purposes of these Terms.

The client may occasionally distribute a copy of a research report, or a portion of the same, from the Website in non-electronic form to a few individuals without charge, provided the client includes all copyright and other proprietary rights notices in the same form in which the notices appear, original source attribution, and the phrase “Used with permission from PrimeInvestor Financial Research Pvt. Ltd.”

While the client may occasionally download and store research reports or information from the Website for his/her personal use, he/she may not otherwise provide others with access to the same. The foregoing does not apply to any sharing functionality we provide through the Website that expressly allows the client to share Content or links to Content with others. In addition, the client may not use Content he/she has downloaded for personal use to develop or operate an automated trading system or for data or text mining.

The client agrees not to rearrange or modify the Content available through the Website. The client agrees not to display, post, frame, or scrape the Content for use on another website, app, blog, product or service, except as otherwise expressly permitted by these Terms. You agree not to create any derivative work based on or containing the research products and Content. The framing or scraping of or in-line linking to the Services or any Content contained thereon and/or the use of webcrawler, spidering or other automated means to access, copy, index, process and/or store any Content made available on or through the Services other than as expressly authorized by us is prohibited.

The client further agrees to abide by exclusionary protocols (e.g., Robots.txt, Automated Content Access Protocol (ACAP), etc.) that may be used in connection with the Research Services. The client may not access parts of the Research Services to which he/she is not authorized, or attempt to circumvent any restrictions imposed on your use or access of the Services.

As a general rule, the client may not use the Content, including without limitation, any Content made available through one of our RSS Feeds, in any commercial product or service, without our express written consent.

The client may not create apps, extensions, or other products and services that use our Content without our permission. The client may not aggregate or otherwise use our Content in a manner that could reasonably serve as a substitute for a subscription to the Website.

The client may not access or view the Services with the use of any scripts, extensions, or programs that alter the way the Services are displayed, rendered, or transmitted to you without our written consent.

The client agrees not to use the Services for any unlawful purpose. We reserve the right to terminate or restrict the client's access to the Website if, in our opinion, the client's use of the Services may violate any laws, regulations or rulings, infringe upon another person's rights or violate these Terms.

Prohibited content: The Website includes comments sections, blogs and other interactive features that allow interaction among clients and between clients and the RA. We call the information posted by or contributed by users “Contributed Content.” In the course of availing of the Research Services or uploading any post or comment on the Website, the client shall not post any Contributed Content that (i) contains nude, semi-nude, sexually suggestive photos, (ii) tends or is likely to abuse, harass, threaten, impersonate or intimidate other users of the Website and/or Research Services, (iii) is lascivious or appeals to the prurient interest or if its effect is such as to tend to deprave and corrupt persons who are likely to use or have access to the Website and/or Services, or (iv) otherwise violates, is prohibited or restricted by applicable law, rule or regulation, is offensive or illegal or violates the rights of, harms or threatens the safety of other users of the Website and/or Services (collectively “Prohibited Content”).

We reserve the right to cease to provide the client with the Research Services or access to the Website, or terminate your subscription, with immediate effect and without notice and liability, for violating these Terms, applicable law, rules or regulations and reserves the right to remove Prohibited Content which is in violation of these Terms, or is otherwise abusive, illegal or disruptive. The determination of whether any content constitutes Prohibited Content, violates these Terms, or is otherwise abusive illegal or disruptive, is subject to the sole determination of the Firm.

Changes to Research Services: We are constantly endeavouring to improve the quality of Research Services provided to our clients. Due to this, the form and nature of the Research Services provided may change from time to time without any prior notice to the client. We reserve the right to introduce and initiate new features, functionalities, components to the Website and/or Research Services and/or change, alter, modify, or discontinue existing ones without any prior notice to the client.

Warranty and liability disclaimer: The Website, Research Services, and all the materials and services, included on or otherwise made available to the client through this Website is provided by the RA on an “as is” and “as available” basis without any representation or warranties, express or implied except otherwise specified in writing. Without prejudice to the foregoing paragraph, the RA does not warrant that:

  • This Website and/or Research Services will be constantly available, or available at all;
  • The information on this Website or provided through the Research Services is complete, true, accurate or not misleading; or
  • The quality of any products, services, information, or other material that you obtain through the Website or Services will meet your expectations.

The RA, to the fullest extent permitted by law, disclaims all warranties, whether express or implied, including the warranty of merchantability, fitness for particular purpose and non-infringement. The RA makes no warranties about the accuracy, reliability, completeness, or timeliness of the Website, Research Services, Content, Contributed Content, Services, software, text, graphics and links.

The RA does not warrant that this Website, Research Services, information, content, materials, or any other material included on or otherwise made available to you through this Website, their servers, or electronic communication sent by the RA are free of viruses or other harmful components.

Nothing on this Website constitutes, or is meant to constitute, advice of any kind.

Indemnification: The client:

  1. Represents, warrants and covenants that no materials of any kind provided by him/her will:
    1. Violate, plagiarise, or infringe upon the rights of any third party, including copyright, trademark, privacy or other personal or proprietary rights; or
    2. Contain libellous, Prohibited Content or other unlawful material;
  2. Hereby agree to indemnify, defend and hold harmless the RA and all of the RA’s officers, directors, owners, agents, customers/clients, information providers, affiliates, licensors and licensees (collectively, the “Indemnified Parties”) from and against any and all liability and costs, including, without limitation, reasonable advocate’s fees, incurred by the Indemnified Parties in connection with any claim arising out of any breach by the client of these Terms or the foregoing representations, warranties and covenants. The client shall cooperate as fully as reasonably required in the defence of any such claim. The RA reserves the right, at its own expense, to assume the exclusive defence and control of any matter subject to indemnification by the client.

Applicable law: This Website, including the Content and Contributed Content and information contained herein, and the provision of Research Services shall be governed by the Securities and Exchange Board of India, laws of the Republic of India and the courts of Chennai, India which shall retain exclusive jurisdiction to entertain any proceedings in relation to any disputes arising out of the same. As such, the laws of India shall govern any transaction completed using this Website.

Information gathered and tracked: Information submitted or collected on the Website or pursuant to the use of the Services is stored in a database. Specifically, we store the username, name, e-mail address, contact number, as submitted or collected on our Website or through the provision of the Research Services. We may use such information to send out occasional promotional materials, including alerts on new Services available, or other promotional and marketing material relating to our clients and customers.

In accordance with the Information Technology Act 2000, the name and the details of the Grievance Officer at PrimeInvestor is provided below:

Mr. Srikanth Meenakshi
PrimeInvestor Financial Research Pvt. Ltd., Registered office: 659, 4th Avenue, D-Sector, Anna Nagar Western Extension, Chennai 600 101.
Email: [email protected]

11. Mandatory notice:

Clients shall be requested to go through Do’s and Don’ts while dealing with RA as specified in SEBI master circular no. SEBI/HO/MIRSD-POD-1/P/CIR/2024/49 dated May 21, 2024 or as may be specified by SEBI from time to time.

12. Optional Centralised Fee Collection Mechanism:

SEBI has operationalized a centralized fee collection mechanism for IA and RA. Under this mechanism, clients shall pay fees to IAs/RAs through a designated platform/portal administered by a recognized Administration and Supervision body. This is an optional mechanism for the registered entities. At this time, PrimeInvestor has opted out of this fee collection mechanism. Therefore, all subscription payments for the Research Services will be through the modes as specified in Clause 5 of these Terms.

Enter the OTP sent to (Edit)
By doing this you agree to our terms & conditions
Didn't receive OTP? Resend

Have an account?
Login To Your Account
OR
Don’t have an account ? Register for free